Olema Pharmaceuticals (OLMA) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Olema Pharmaceuticals (NASDAQ: OLMA) in the last few weeks:

• 3/27/2026 – Olema Pharmaceuticals is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 3/19/2026 – Olema Pharmaceuticals is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $40.00 price target on the stock.
• 3/18/2026 – Olema Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00. They now have an “overweight” rating on the stock.
• 3/18/2026 – Olema Pharmaceuticals had its price target lowered by The Goldman Sachs Group, Inc. from $38.00 to $27.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Olema Pharmaceuticals had its price target raised by Citigroup Inc. from $60.00 to $62.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Olema Pharmaceuticals had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a “buy” rating on the stock.
• 3/9/2026 – Olema Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 3/9/2026 – Olema Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 3/9/2026 – Olema Pharmaceuticals had its price target lowered by HC Wainwright from $45.00 to $38.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Olema Pharmaceuticals is now covered by Stifel Nicolaus. They set a “buy” rating and a $48.00 price target on the stock.

Insider Activity at Olema Pharmaceuticals

In other news, insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $28.73, for a total value of $2,873,000.00. Following the transaction, the insider directly owned 139,727 shares of the company’s stock, valued at $4,014,356.71. The trade was a 41.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David C. Myles sold 50,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $27.60, for a total transaction of $1,380,000.00. Following the completion of the sale, the insider owned 542,761 shares of the company’s stock, valued at approximately $14,980,203.60. This trade represents a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 217,311 shares of company stock valued at $5,965,254 over the last quarter. 16.36% of the stock is owned by insiders.

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.